Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 29, Issue 12, Pages E80-E90Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e3181faa6be
Keywords
clinical trial; pneumococcal conjugate vaccine
Categories
Funding
- Wyeth Pharmaceuticals, Collegeville, PA
- NIHR Oxford Partnership Comprehensive Biomedical Research Centre
- Thames Valley Comprehensive Clinical Research network
- South West Local Research Network
- Wyeth
Ask authors/readers for more resources
Background: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM197 was evaluated in a randomized, double-blind, controlled infant study. Methods: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). Specific antibody responses were assessed at age 5, 12, and 13 months. Results: At 13 months of age, >97% of PCV13 recipients had pneumococcal serotype-specific serum IgG concentrations >= 0.35 mu g/mL for each vaccine serotype except serotype 3 (88.2%), and at least 93% of PCV13 recipients had OPA titers >= 1:8 for each serotype. At 5 months, 110/114 (96.5%) of PCV13 recipients and 100/102 (98.0%) of PCV7 recipients had serum anti-PRP (Hib) IgG concentration >= 0.15 mu g/mL (difference, 1.5%; CI, -7.1%-3.7%), while 119/120 (99.2%) and 117/118 (99.2%), respectively, had MenC serum bactericidal assay titers of >= 1:8. All PCV13 recipients and 110/113 (97.3%) of PCV7 recipients had IgG concentrations against fimbrial agglutinogens of >= 2.2 EU/mL; IgG concentrations for the remaining pertussis antigens were >= 5 EU/mL for all participants. Local reactions and systemic events were similar in the PCV13 and PCV7 groups. Conclusions: A 2-, 4-, and 12-month course of PCV13 was immunogenic for all 13 vaccine serotypes and was well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available